LINCS Extended Metadata Standard: Proteins
Abbreviation: LINCS 2: Proteins
This record replaces or incorporates the following deprecated resources:
Developed in United States
Created in 2015
Knowledge Domains BETA
How to cite this record FAIRsharing.org: LINCS 2: Proteins; LINCS Extended Metadata Standard: Proteins; DOI: https://doi.org/10.25504/FAIRsharing.xjx7vy; Last edited: Nov. 23, 2018, 11:27 a.m.; Last accessed: Dec 16 2018 4:56 p.m.
Record added: April 27, 2016, 2:15 p.m.
Record updated: Oct. 22, 2016, 7:50 p.m. by The FAIRsharing Team.
Edits to 'https://fairsharing.org/FAIRsharing.xjx7vy' by 'The FAIRsharing Team' at 19:50, 22 Oct 2016 (approved): 'homepage' has been modified: Before: http://www.lincsproject.org/data/data-standards/ After: http://www.lincsproject.org/LINCS/data/standards
Edits to 'https://fairsharing.org/FAIRsharing.xjx7vy' by 'The FAIRsharing Team' at 16:34, 28 Sep 2016 (approved): 'name' has been modified: Before: LINCS Production Phase 2 Extended Metadata Standard: Proteins After: LINCS Extended Metadata Standard: Proteins
No XSD schemas defined
Conditions of Use
Metadata Standard and Data Exchange Specifications to Describe, Model, and Integrate Complex and Diverse High-Throughput Screening Data from the Library of Integrated Network-based Cellular Signatures (LINCS).
Vempati UD,Chung C,Mader C,Koleti A,Datar N,Vidovic D,Wrobel D,Erickson S,Muhlich JL,Berriz G,Benes CH,Subramanian A,Pillai A,Shamu CE,Schurer SC
J Biomol Screen 2014
No semantic standards defined
Models and Formats
No syntax standards defined
No identifier schema standards defined
The LINCS Data Portal provides a unified interface for searching LINCS dataset packages and reagents. LINCS data are being made openly available as a community resource through a series of data releases, so as to enable scientists to address a broad range of basic research questions and to facilitate the identification of biological targets for new disease therapies. LINCS datasets consist of assay results from cultured and primary human cells treated with bioactive small molecules, ligands such as growth factors and cytokines, or genetic perturbations. Many different assays are used to monitor cell responses, including assays measuring transcript and protein expression; cell phenotype data are captured by biochemical and imaging readouts. Assays are typically carried out on multiple cell types, and at multiple timepoints; perturbagen activity is monitored at multiple doses.
This record is not implemented by any policy.